Dernières nouvelles pour Qiagen (NYSE:QGEN) Stock

Qiagen

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Qiagen NV

Qiagen N.V.

<ul>
<li>Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS</li>
<li>Return of approximately $300 million – maximum approved by shareholders – set to be completed in late January 2025</li>
<li>Builds on approximately $300 million returned to shareholders in early 2024 as part of commitment to return at least $1 billion through end-2028</li>
</ul>
QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.
QIAGEN announced earlier in January plans for the repurchase, which comes after QIAGEN returned approximately $300 million to shareholders in early 2024 also through a synthetic share repurchase. Together, these two programs represent approximately $600 million of a commitment to return at least $1 billion to shareholders by the end of 2028 (absent M&amp;A opportunities).

News

Buybacks

QGEN

Qiagen Announces $300M Capital Return Via Synthetic Share Repurchase By January 2025; Follows $300M Returned In Early 2024, Aiming For $1B Total By 2028. Plan Involves 3% Reduction In Issued Shares, Enhancing EPS

QIAGEN has decided to implement the maximum USD300 million value of the mandate given at the Annual General Meeting in June 2024, where shareholders gave virtually unanimous approval for the related resolutions. This approach is designed to return cash to shareholders in a more efficient way than through a traditional open-market repurchase program. It would also enhance earnings per share (EPS) through the reduction in outstanding shares. The synthetic share repurchase will become effective on January 28, 2025, and will be settled in line with market convention in the subsequent days

Qiagen Said Sunday, It Will Return ~$300M To Shareholders Through A Synthetic Share Repurchase

<ul>
<li>QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold increase from prior capability for up to five targets</li>
<li>No instrument hardware changes required for upgraded capability thanks to new QIAcuity Software 3.1 update and launch of QIAcuity High Multiplex Probe PCR Kit</li>
<li>New QIAcuity digital PCR capabilities helps make lab work more productive and cost-efficient through savings on time, reagents consumption and use of precious sample materials</li>
</ul>

QIAGEN Enhances QIAcuity Digital PCR With High-Order Multiplexing For Simultaneous Detection Of Up To12 Targets

<ul>
<li>New QIAstat-Dx Gastrointestinal Panel 2 Mini B&amp;V (bacterial and viral) tailored to provide fast answers for outpatient diagnosis of gastrointestinal conditions</li>
<li>QIAGEN the first to offer both comprehensive and targeted syndromic gastrointestinal panels, giving clinicians unmatched flexibility to optimize diagnostics for individual patients</li>
<li>QIAstat-Dx Rise higher-capacity instrument version to be submitted in early 2025 for U.S. regulatory clearance, builds on groundbreaking 2024 clearances of four QIAstat-Dx Panels</li>
</ul>

Reported Earlier, QIAGEN Gains FDA Clearance For QIAstat-Dx Mini Gastrointestinal Panel, Supporting Year-Round Outpatient Care

Morgan Stanley analyst Steve Beuchaw downgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Overweight to Equal-Weight and lowers the price target from $50 to $48.

Downgrades

Price Target

Analyst Ratings

Morgan Stanley Downgrades Qiagen to Equal-Weight, Lowers Price Target to $48

<ul>
<li>Ingenuity Pathway Analysis Interpret extends analysis capabilities of human-curated knowledge base with AI technology</li>
<li>AI-extension highlights key biological elements at work and provides summarized results and interpretations in a sharable web document, speeding up interpretation</li>
<li>Ingenuity Pathway Analysis Interpret unlocks the full potential of biological data by streamlining interpretation process and delivering actionable insights for experiments</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.
Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable insights, helping researchers understand which genes are involved in a disease, a biological process or a response to a drug or environmental condition.
IPA, which forms the foundation of IPA Interpret, has over 50,000 citations and a high-quality, manually curated knowledge base. This widely recognized platform structures and integrates causal biomedical relationships between genes, diseases, functions, targets, drugs chemicals, and other objects. With IPA's curated knowledge base, scientists can confidently predict and validate novel target-disease and drug-disease relationships.
By combining this extensive knowledge with advanced analyses and AI algorithms, IPA Interpret now automatically analyzes, compares, and contextualizes complex gene expression datasets available in IPA, identifying key biological processes, pathways, and networks, in a streamlined web-page report.

Biotech

General

QIAGEN Launches AI-Extension Of Ingenuity Pathway Analysis For Automatic Interpretation Of Biological Data

Jefferies analyst Tycho Peterson assumes Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Buy rating and raises Price Target to $54.

Initiation

Jefferies Assumes Qiagen at Buy, Raises Price Target to $54

<ul>
<li>EZ2 Connect for automated nucleic acid purification has reached over 1,000 placements worldwide, contributing to a global installed base of more than 5,500 EZ series instruments</li>
<li>Comprehensive portfolio of EZ2 Connect automated kits provides research and clinical labs with more time for in-depth analyses rather than manual processing
<ul>
<li>Launch of EZ2 PowerFecal Pro DNA/RNA Kit expands portfolio into gut microbiome research, builds on EZ2 Connect kits for applications such as diagnostics, genomics and cancer research, molecular epidemiology and forensics</li>
</ul>
</li>
</ul>

QIAGEN Achieves Milestone With Over 1,000 Placements Of EZ2 Connect Sample Preparation Instrument

<ul>
<li>New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment</li>
<li>Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx, supporting the development of infectious disease tests and precision medicine applications</li>
</ul>

Reported Thursday, QIAGEN Boosts QIAstat-Dx With New Barcelona Hub For Infectious Disease And Precision Medicine Testing

On November 13, 2024, Syros Pharmaceuticals, Inc. (the "Company") gave notice to QIAGEN Manchester Limited ("QIAGEN") of its election to terminate the Master Collaboration Agreement dated March 7, 2022 (the "Agreement") relating to the development and commercialization of an assay as a companion diagnostic test for use with tamibarotene as a result of the failure of the Company's SELECT-MDS-1 Phase3 trial evaluating tamibarotene to meet its primary endpoint of complete response rate, which was previously disclosed on the Company's Current Report on Form 8-Kfiled with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2024. The termination will be effective 90 days following such notice.

SYRS

Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022

Contracts

QIAGEN Collaborates With McGill University On Microbiome Research; Terms Not Disclosed

QIAGEN has reaffirmed its FY 2024 sales outlook for at least $1.985 billion CER based on the solid core business performance in the first nine months of the year. The outlook for adjusted diluted EPS has been increased to at least $2.19 CER (previously $2.10 CER at start of 2024), while the adjusted operating income margin target has been reaffirmed for at least 28.5% compared to 26.9% in 2023.

Guidance

QIAGEN Reaffirms FY24 Sales Of At Least $1.985B Vs $1.98B Est.; Increases EPS Guidance From $2.10 CER To At Least $2.19 CER Vs $2.15 Est.

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.54 by 5.56 percent. This is a 14 percent increase over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $502.00 million which beat the analyst consensus estimate of $491.75 million by 2.09 percent. This is a 5.49 percent increase over sales of $475.89 million the same period last year.

Earnings

Earnings Beats

Qiagen Q3 Adj $0.57 Beats $0.54 Estimate, Sales $502.00M Beat $491.75M Estimate

QIAGEN Gains FDA Clearance For Rapid QIAstat-Dx Meningitis/Encephalitis Panel, Boosting Emergency Diagnostics

QIAGEN Secures FDA Clearance For Qiastat-Dx Mini Panel, Enhancing Precision In Outpatient Respiratory Care

HSBC analyst Shubhangi Gupta downgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Buy to Hold.

HSBC Downgrades Qiagen to Hold

As the third-quarter earnings season approaches, Goldman Sachs has issued a note identifying key stock opportunities for investors looking to profit <a href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist">from financial results.</a>
Analyst John Marshall and his team shared their insights on Thursday, highlighting 18 stocks that could benefit from upward earnings revisions and seven stocks likely to face downward revisions.
<h3 class="wp-block-heading">The &#8216;Stock Picker&#8217;s Year&#8217;: 10% Upside In S&amp;P 500</h3>
Goldman Sachs analysts call 2024 "the year of the stock picker," emphasizing the importance of selective investing in a volatile earnings environment.
According to the investment bank&#8217;s latest projections, the average S&amp;P 500 stock could see a 10% upside over the next 12 months. 
"We see relief rally potential," Marshall stated in his note. "Directional positioning in the options market is balanced, a much better set-up than this time last quarter."
The analysts also observed that activity in options markets, both from hedge funds and retail traders, has decreased recently, signaling a "wait-and-see" approach as investors prepare for third-quarter earnings reports and the upcoming U.S. elections.
<h3 class="wp-block-heading">Earnings Season Volatility Remains Elevated</h3>
Goldman Sachs highlighted that single-stock volatility surrounding earnings events remains at a 14-year high. 
This trend, driven by critical market debates on topics like artificial intelligence, interest rates, and the upcoming election, is expected to continue through the remainder of the year.
&#8220;We expect earnings day moves to remain elevated as most of the key debates for the market have winners and losers in the equity space,&#8221; the note added. 
With this heightened volatility, the firm continues to recommend options-based strategies, advising investors to consider buying options ahead of earnings events and selling options between earnings periods to capitalize on price movements.
<h3 class="wp-block-heading">18 Stocks Goldman Sachs Is Bullish On For Third-Quarter Earnings</h3>
Goldman Sachs&#8217; analysts have identified 18 stocks they believe are primed for upside as earnings revisions could be favorable. These stocks span a variety of sectors, from energy and financials to healthcare and technology.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>)</td>
<td>Discretionary</td>
<td>Nov. 15</td>
</tr>
<tr>
<td>Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>)</td>
<td>Energy</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>Financials</td>
<td>Oct. 15</td>
</tr>
<tr>
<td>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>Financials</td>
<td>Oct. 16</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</td>
<td>Healthcare</td>
<td>Oct. 23</td>
</tr>
<tr>
<td>Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>Healthcare</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>Qiagen NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>AZEK Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>)</td>
<td>Industrials</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>)</td>
<td>TMT</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>TMT</td>
<td>Dec. 6</td>
</tr>
<tr>
<td>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>TMT</td>
<td>Nov. 25</td>
</tr>
<tr>
<td>Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)</td>
<td>TMT</td>
<td>Nov. 13</td>
</tr>
<tr>
<td>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>TMT</td>
<td>Nov. 21</td>
</tr>
<tr>
<td>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>TMT</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</td>
<td>Utilities</td>
<td>Nov. 4</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">7 Stocks Goldman Sachs Is Bearish On For Third-Quarter Earnings</h3>
In contrast, the investment bank has identified seven stocks that they expect to face downward earnings revisions in the third quarter, advising investors to exercise caution.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choice Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>)</td>
<td>Discretionary</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>)</td>
<td>Energy</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Janus Henderson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>)</td>
<td>Financials</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>LyondellBasell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>Materials</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>)</td>
<td>Staples</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</td>
<td>Staples</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Upstart Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">Fed&#8217;s Goolsbee Downplays Inflation Uptick, Economists Hold Steady On November Rate Interest Rate Cut Call</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

SNOW

TOST

UPST

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'

These updates &ndash; designed for use on the QIAsymphony and EZ2 Connect instruments &ndash; are designed to enable research and molecular diagnostics laboratories to efficiently improve results when processing larger sample volumes that are crucial for oncology research and diagnostics.
The upgrades add to the PAXgene Urine Liquid Biopsy Set recently launched by PreAnalytiX, QIAGEN&#39;s joint venture with BD. The new set, which will be commercialized by QIAGEN, enables reliable analysis of cfDNA from urine more than ever before.

QIAGEN Reveals Key Updates To Its Sample Technologies Solutions For Non-Invasive Liquid Biopsy Applications

QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics. The instrument and accessories are 510(k) exempt in the U.S. and IVDR-certified for diagnostic use in Europe.
QIAcuityDx streamlines clinical testing by providing highly precise, absolute quantitation of target DNA and RNA, supporting applications with less invasive liquid biopsies. These capabilities make it an ideal tool for monitoring cancer progression, complementing routine cancer diagnoses, which are typically performed using Next Generation Sequencing (NGS).
QIAGEN is rapidly expanding the application menu available on QIAcuityDx-System, with a new BCR::ABL assay for oncohematology planned for FDA submission in 2025. The platform also provides immediate access to QIAGEN's full portfolio of research-use products and applications via its GeneGlobe platform. QIAGEN has already signed three partnerships with pharmaceutical companies to develop companion diagnostics on the QIAcuityDx, moving digital PCR into precision medicine. In addition, QIAGEN plans to further enhance the future assay portfolio by collaborating with third parties, who will develop their own assays for the platform.

QIAGEN Launches QIAcuityDx Digital PCR System For Clinical Testing In Oncology

QIAGEN Receives European IVDR Certification For QIAstat-Dx Syndromic Testing Instruments And Assays

Qiagen ( ($QGEN) ) just unveiled an update. QIAGEN has announced a plan to return approximately $300 million to shareholders through a synthetic sh...

QIAGEN Announces $300 Million Synthetic Share Repurchase Plan

The latest announcement is out from Qiagen ( ($QGEN) ). On January 11, 2025, Qiagen N.V. was informed by the Netherlands Authority for the Financia...

Qiagen N.V. Voting Rights Update: BlackRock's Significant Stake Disclosed

The latest announcement is out from Qiagen ( ($QGEN) ). The Netherlands Authority for the Financial Markets (AFM) has informed Qiagen N.V. of a sig...

Qiagen Announces BlackRock's Significant Voting Rights in Recent AFM Disclosure

Kepler Capital analyst Maja Pataki maintained a Hold rating on Qiagen (QGEN – Research Report) on January 14 and set a price target of €41.00. The ...

Qiagen (QGEN) Gets a Hold from Kepler Capital

Qiagen ( ($QGEN) ) has provided an update. On January 16, 2025, QIAGEN announced the completion details of a synthetic share repurchase plan to ret...

QIAGEN Finalizes $300 Million Synthetic Share Repurchase Plan

Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer

Life sciences stocks fall on NIH funding concerns

These are the upcoming stock splits for the week of January 27 to January 31, based on&nbsp;TipRanks' Stock Splits Calendar. A&nbsp;stock split&nbs...

Upcoming Stock Splits This Week (January 27 to January 31) – Stay Invested

An announcement from Qiagen ( ($QGEN) ) is now available. Qiagen N.V. has been notified by the Netherlands Authority for the Financial Markets (AFM...

Qiagen's Institutional Investment Spotlight: BlackRock's Voting Rights Revealed

In a report released on January 27, Maja Pataki from Kepler Capital maintained a Hold rating on Qiagen (QGEN – Research Report), with a price targe...

Comments

Qiagen

Actualités

Dernières nouvelles pour Qiagen (NYSE:QGEN) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL